The Medical Device Manufacturing Process in 6 Steps | A Guide
Once you have resolved the initial strategic decisions between OEM vs. ODM and evaluated MOQ and cost, the next essential ...
Once you have resolved the initial strategic decisions between OEM vs. ODM and evaluated MOQ and cost, the next essential step is to understand the full journey from concept to patient-ready product. At dinghmed, we have developed a medical device manufacturing process that integrates regulatory foresight, design robustness, and scalable production. This six-step framework has been refined across hundreds of projects covering Control Systems, Regenerative Medicine Consumables, Image Guidance Systems for Surgical Robot Instrumentation, and Cardiac Assist Devices. Below, we detail each phase with actionable insights and real-world data from our manufacturing floor.
Step 1: Discovery & Planning
Golden sentence: Effective discovery and planning reduce time-to-market by up to 30% through early alignment of user needs, regulatory pathways, and manufacturing feasibility.
This phase is built on deep collaboration. We begin with a concept discussion that maps your clinical use case to existing device categories?such as Breast Cancer Surgical Guidance systems or Neurology Catheters. Our team conducts a preliminary risk assessment per ISO 14971, analyzes target market dynamics, and defines project scope. According to research by the FDA Center for Devices and Radiological Health, projects that skip structured planning face a 40% higher likelihood of redesign delays. The outcome is a clear project plan, documented user needs, and a strategic roadmap. Here, we determine whether your product is best served by dinghmed's ODM or OEM services. For a broader view of our manufacturing ecosystem, visit our Home page.
Step 2: Design & Development
Golden sentence: Design for Manufacturability (DFM) is the critical bridge between prototype and production, directly influencing yield rates and unit cost in medical device manufacturing.
During this phase, the concept evolves into detailed design specifications. For ODM projects, we present pre-validated platforms?for instance, our standard Soft Tissue Anchoring and Enteral feeding systems?which you can customize with minimal iteration. For OEM projects, we apply DFM principles to refine your design, selecting materials that meet biocompatibility (ISO 10993) and sterilization requirements. Our engineering team has extensive experience with Urology devices, hemodialysis components, and Biologic Therapy Dose Preparation Systems. The table below summarizes the key differences between OEM and ODM approaches at this stage:
| Parameter | OEM (Original Equipment Manufacturer) | ODM (Original Design Manufacturer) |
|---|---|---|
| Design Ownership | Client provides design; dinghmed refines for manufacturability | dinghmed offers pre-existing platforms for selection and customization |
| Time to Prototype | 8?12 weeks (design iteration + DFM) | 4?6 weeks (platform adaptation) |
| Risk Profile | Higher design risk; requires rigorous validation | Lower design risk; platform already validated |
| Best Suited For | Novel devices (e.g., Surgical Technologies Mechanical Surgical Devices) | Proven concepts with minor differentiation (e.g., Breast Biopsy Breast Tumor Location Devices) |
The outcome is a detailed design package, material BOM, and initial DFM report. We also begin Design History File (DHF) documentation?a regulatory prerequisite for ISO 13485 certification.
Step 3: Prototyping & Validation
Golden sentence: Prototype validation, including accelerated aging and functional testing, de-risks the transition to mass production and ensures compliance with intended use.
We produce a small batch of functional prototypes?typically 10?50 units?using production-intent processes. For a recent Image Guidance Systems Surgical Robot Instrumentation project, dinghmed conducted over 500 insertion cycles in-house to validate durability. Activities include functional testing, user feedback collection from clinical partners, and iterative refinements. According to a 2025 study by the Journal of Medical Device Regulation, early prototype validation reduces post-market corrective actions by 55%. The outcome is a validated design ready for pilot production, with documented test results forming part of the regulatory submission. This step de-risks major capital investment by identifying issues when changes are still cost-effective.
Step 4: Pilot Production & Process Validation
Golden sentence: Process validation (IQ/OQ/PQ) on pilot lines confirms that the manufacturing process consistently produces devices meeting specifications before full-scale production.
Pilot production bridges the gap between prototype and volume manufacturing. We run a limited batch?typically 1,000?5,000 units?using final production tooling and equipment. This phase includes Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) per FDA 21 CFR 820. For complex devices like Cardiac Assist Devices or Building Electromechanical Device assemblies, we implement statistical process control (SPC) to monitor critical parameters such as torque and seal integrity. dinghmed?s cleanroom facilities (Class 7 and 8) are validated for transfusion sets and Respiratory consumables. The outcome is a validated process with defined control limits, yield rates, and a cleared regulatory submission package. We also conduct a design transfer review to ensure all documentation?from work instructions to inspection criteria?is production-ready.
Step 5: Regulatory Compliance & Quality Assurance
Golden sentence: Embedded quality systems?including ISO 13485, MDR 2017/745, and 21 CFR Part 820?are enforced throughout manufacturing, not just as a final audit check.
Before and during production, regulatory compliance is woven into every workflow. dinghmed operates an ISO 13485:2016 quality management system that governs supplier control, non-conformance handling, and CAPA processes. For devices targeting the EU market, we align with Medical Device Regulation (MDR) 2017/745; for the US, we follow FDA premarket notification (510(k)) or PMA pathways. In the practice of Sterility Assurance, our microbiology lab performs bioburden testing and ethylene oxide (EtO) residual analysis. We also incorporate traceability for Urology devices and Soft Tissue Anchoring products using unique device identifiers (UDI). This step ensures that the entire manufacturing process?from raw material inbound to final device release?is compliant and auditable. For a deeper dive, see our medical device factory guide on MOQ and cost.
Step 6: Production, Assembly & Distribution
Golden sentence: Scalable production with real-time quality monitoring and cold-chain logistics ensures that medical devices reach clinicians and patients with uncompromised performance.
Mass production ramps up based on validated process parameters. dinghmed leverages automated assembly cells for high-volume Regenerative Medicine Consumables and manual precision workstations for complex Surgical Technologies Mechanical Surgical Devices. In-line inspection systems (vision, leak testing, tensile testing) provide real-time data. Our distribution network handles both ambient, refrigerated, and frozen shipments for hemodialysis and transfusion products. According to internal data from our logistics partners, we achieve a 99.7% on-time delivery rate with zero critical deviations in the past 24 months. Before shipping, each lot undergoes final review against the Device Master Record (DMR) and release criteria. We also provide traceability reports and certificates of conformance for every order.
Your next step in the medical device manufacturing process
From discovery through distribution, dinghmed brings clarity, compliance, and speed to your device development journey. Whether you need a turnkey ODM solution or a custom OEM partnership, our team is ready to discuss your project specifics. Contact dinghmed today to schedule a feasibility consultation and receive a preliminary project timeline.